SCHEMBL17895671

SCHEMBL17895671

CC(C)(C)C(O)(c1cccnc1)c1nc2ccc(Br)cc2s1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 2/20 0.40
▸ RORC P51449 4/20 0.39
▸ RAB9A P51151 3/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ DYRK1A Q13627 1/20 0.38
▸ CASR P41180 4/20 0.38
▸ CYP19A1 P11511 3/20 0.36
▸ PIK3CA P42336 2/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ PIP5K1C O60331 1/20 0.36
▸ PI4KA P42356 1/20 0.36
▸ PI4KB Q9UBF8 1/20 0.36
▸ PIK3CG P48736 1/20 0.35
▸ APP P05067 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17895668 0.88 CASR (0.46) PPARARORCRAB9ANPC1CYP1A2
SCHEMBL17895705 0.83 RORC (0.39) PPARARORCRAB9ANPC1CYP1A2
SCHEMBL17895712 0.83 CYP3A4 (0.45) PPARARORCRAB9ANPC1CYP1A2
SCHEMBL17895558 0.81 RORC (0.37) PPARARORCRAB9ANPC1CYP1A2
SCHEMBL17895693 0.80 PPARA (0.38) PPARARORCRAB9ANPC1CYP1A2
SCHEMBL17895643 0.80 CASR (0.43) PPARARORCRAB9ANPC1CYP1A2
SCHEMBL17895611 0.74 PIK3CA (0.39) PPARARORCRAB9ANPC1CYP1A2
SCHEMBL17895605 0.74 CYP3A4 (0.45) PPARARORCCYP3A4DYRK1ACASR
SCHEMBL7873642 0.72 PPARA (0.51) PPARARAB9ANPC1CYP1A2CYP3A4
SCHEMBL16230653 0.72 CYP19A1 (0.56) CYP1A2CYP3A4CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434234-B2 Methods and agents for treating disease ANGION BIOMEDICA CORP. (US) 2022-09-06 — — US claimed
CN-107531631-B Methods and agents for treating diseases 安吉昂生物医药公司 2021-09-03 — — CN disclosed
EP-3240778-A1 METHODS AND AGENTS FOR TREATING DISEASE Angion Biomedica Corp. (US) 2017-11-08 — — EP disclosed
WO-2016109492-A1 METHODS AND AGENTS FOR TREATING DISEASE ANGION BIOMEDICA CORP (US) 2016-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434234-B2 Methods and agents for treating disease REN, NR3C2, CYP11B2 PPARA 361/4885RORC 421/4885RAB9A 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback